论文部分内容阅读
目的探讨坎地沙坦联合依那普利对陈旧性心肌梗死(OMI)并心力衰竭患者血清超敏C反应蛋白(hs-CRP)水平和心功能的影响。方法选取2013年1月—2015年12月宝鸡市第三人民医院收治的OMI并心力衰竭患者84例,随机分为对照组和观察组,每组42例。对照组患者采用常规治疗,观察组患者在常规治疗基础上给予坎地沙坦联合依那普利,两组患者均连续治疗2周。比较两组患者临床疗效、治疗前后血清hs-CRP水平及左心室射血分数(LVEF)、治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者血清hs-CRP水平和LVEF比较,差异无统计学意义(P>0.05);治疗后,观察组患者血清hs-CRP水平低于对照组,LVEF高于对照组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论坎地沙坦联合依那普利可改善OMI并心力衰竭患者心功能,降低血清hs-CRP水平。
Objective To investigate the effect of candesartan and enalapril on serum hs-CRP level and cardiac function in patients with heart failure and myocardial infarction (AMI). Methods Eighty-four OMI patients with heart failure admitted to the Third People’s Hospital of Baoji from January 2013 to December 2015 were randomly divided into control group and observation group, with 42 cases in each group. Patients in the control group received conventional therapy. Patients in the observation group were given candesartan plus enalapril on a regular basis, and both groups were treated for 2 weeks. The clinical efficacy, serum hs-CRP level and left ventricular ejection fraction (LVEF) before and after treatment were compared between the two groups. The incidence of adverse reactions during the treatment period was compared. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, serum hs-CRP levels and LVEF were not significantly different between the two groups (P> 0.05). After treatment, serum hs-CRP level in the observation group was lower than that in the control group, and LVEF was higher in the observation group than in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05). Conclusions Candesartan and enalapril can improve cardiac function and reduce serum hs-CRP level in OMI patients with heart failure.